2015 Fiscal Year Final Research Report
Laboratory Medicine of Lysophospholipids
Project/Area Number |
25253040
|
Research Category |
Grant-in-Aid for Scientific Research (A)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Laboratory medicine
|
Research Institution | The University of Tokyo |
Principal Investigator |
Yatomi Yutaka 東京大学, 医学部附属病院, 教授 (60200523)
|
Research Collaborator |
KURANO Makoto 東京大学, 医学部附属病院, 助教 (60621745)
IKEDA Hitoshi 東京大学, 医学部附属病院, 准教授 (80202422)
|
Project Period (FY) |
2013-10-21 – 2016-03-31
|
Keywords | 臨床検査医学 / リゾリン脂質 / リゾホスファチジン酸 / スフィンゴシン1-リン酸 / リゾホスファチジルセリン / オートタキシン / アポリポタンパク質M / ホスファチジルセリン特異的ホスホリパーゼA1 |
Outline of Final Research Achievements |
It is established that lysophospholipids constitute a new family of lipid mediators and are involved in a broad range of (patho)physiological actions. We have examined the involvement of lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P), and lysophosphatidylserine (LysoPS) in human diseases and pursued the clinical introduction of the measurement of these lysophospholipids and their related proteins; LPA, S1P, LysoPS are the most well characterized lysophospholipids. Autotaxin (ATX) reflects the LPA level in vivo, and ATX assay kit is promising as an IVD kit. Furthermore, the minor apolipoprotein ApoM is the carrier of S1P and can be a surrogate marker of S1P while phosphatidylserine-specific phospholipase A1 (PS-PLA1), which produces LysoPS, can be a biomarker reflecting the in vivo action of LysoPS. We have succeeded in the establishment of the assay systems not only for ATX but also for ApoM and PS-PLA1, and revealed the clinical importance of their measurements.
|
Free Research Field |
病態検査学
|